Literature DB >> 11384677

A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology.

P Sehr1, K Zumbach, M Pawlita.   

Abstract

An enzyme-linked immunosorbent assay (ELISA) system has been developed that uses glutathione crosslinked to casein as capture protein to bind recombinant protein antigens fused to N-terminal glutathione S-transferase (GST). The method allows simple and efficient immobilization and one-step purification of overexpressed recombinant antigens from crude lysates on ELISA plates coated with glutathione casein. Several antigens can be tested in parallel under the same conditions without the need to biochemically purify or renature the proteins. An additional undecapeptide epitope fused to the C-terminus of each antigen permits the detection and quantification of any full-length protein antigen bound to the ELISA plate with one single monoclonal antibody. The ELISA system was applied with four antigens to detect antibodies against E6 and E7 proteins of human papillomavirus types 16 and 18. Antibody reactivities of 164 sera from patients with cervical carcinoma and healthy individuals were in good agreement with those determined using a previously established capture ELISA with biochemically purified and renatured proteins as antigens although the GST capture ELISA was more sensitive with no loss of specificity. The GST capture ELISA could be adapted to provide standardized antibody assays for many protein antigens.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11384677     DOI: 10.1016/s0022-1759(01)00376-3

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  73 in total

1.  Sunlight exposure and cutaneous human papillomavirus seroreactivity in basal cell and squamous cell carcinomas of the skin.

Authors:  Michelle R Iannacone; Wei Wang; Heather G Stockwell; Kathleen O'Rourke; Anna R Giuliano; Vernon K Sondak; Jane L Messina; Richard G Roetzheim; Basil S Cherpelis; Neil A Fenske; Kristina M Michael; Tim Waterboer; Michael Pawlita; Dana E Rollison
Journal:  J Infect Dis       Date:  2012-06-01       Impact factor: 5.226

2.  Development of bead-based immunoassay to quantify neutralizing antibody for human papillomavirus 16 and 18.

Authors:  Hai-Bo Liu; Pankaj Kumar Chaturvedi; Gantumur Battogtokh; Hyo Joo Bang; In-Wook Kim; Yong-Wan Kim; Kye-Shin Park; Woong Shick Ahn
Journal:  Mol Biotechnol       Date:  2013-06       Impact factor: 2.695

Review 3.  Measurement of biomarker proteins for point-of-care early detection and monitoring of cancer.

Authors:  James F Rusling; Challa V Kumar; J Silvio Gutkind; Vyomesh Patel
Journal:  Analyst       Date:  2010-07-08       Impact factor: 4.616

4.  A novel peptide motif binding to and blocking the intracellular activity of the human papillomavirus E6 oncoprotein.

Authors:  Susanne Dymalla; Martin Scheffner; Elvira Weber; Peter Sehr; Claudia Lohrey; Felix Hoppe-Seyler; Karin Hoppe-Seyler
Journal:  J Mol Med (Berl)       Date:  2008-12-21       Impact factor: 4.599

5.  Presence of DNA of human papillomavirus 16 but no other types in tumor-free tonsillar tissue.

Authors:  Renwei Chen; Peter Sehr; Tim Waterboer; Ilmo Leivo; Michael Pawlita; Antti Vaheri; Leena-Maija Aaltonen
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

6.  Cutaneous alpha, beta and gamma human papillomaviruses in relation to squamous cell carcinoma of the skin: a population-based study.

Authors:  Shohreh F Farzan; Tim Waterboer; Jiang Gui; Heather H Nelson; Zhongze Li; Kristina M Michael; Ann E Perry; Steven K Spencer; Eugene Demidenko; Adele C Green; Michael Pawlita; Margaret R Karagas
Journal:  Int J Cancer       Date:  2013-04-22       Impact factor: 7.396

7.  Re-detection vs. new acquisition of high-risk human papillomavirus in mid-adult women.

Authors:  Tsung-Chieh Jane Fu; Joseph J Carter; James P Hughes; Qinghua Feng; Stephen E Hawes; Stephen M Schwartz; Long Fu Xi; Taylor Lasof; Joshua E Stern; Denise A Galloway; Laura A Koutsky; Rachel L Winer
Journal:  Int J Cancer       Date:  2016-08-04       Impact factor: 7.396

8.  The seroprevalence of human papillomavirus by immune status and by ethnicity in London.

Authors:  Delphine Casabonne; Tim Waterboer; Kristina M Michael; Michael Pawlita; Liza Mitchell; Robert Newton; Catherine Harwood; Charlotte Proby
Journal:  Infect Agent Cancer       Date:  2009-09-14       Impact factor: 2.965

9.  Association of Merkel cell polyomavirus-specific antibodies with Merkel cell carcinoma.

Authors:  Joseph J Carter; Kelly G Paulson; Greg C Wipf; Danielle Miranda; Margaret M Madeleine; Lisa G Johnson; Bianca D Lemos; Sherry Lee; Ashley H Warcola; Jayasri G Iyer; Paul Nghiem; Denise A Galloway
Journal:  J Natl Cancer Inst       Date:  2009-09-23       Impact factor: 13.506

10.  Coronavirus immunoreactivity in individuals with a recent onset of psychotic symptoms.

Authors:  Emily G Severance; Faith B Dickerson; Raphael P Viscidi; Ioannis Bossis; Cassie R Stallings; Andrea E Origoni; Anne Sullens; Robert H Yolken
Journal:  Schizophr Bull       Date:  2009-06-02       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.